Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

Autor:	T.K. Owonikoko, K.P. Papadopoulos, M.L. Johnson, M. Gil Martín, V. Moreno, A.K. Salama, E. Calvo, N.S. Yee, H. Safran, R. Aljumaily, D. Mahadevan, J. Niu, K. Kal Mohan, J. Li, E. Stankevich, M. Mathias, I. Lowy, M.G. Fury, H.M. Babiker
Rok vydání:	2018
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 29:x25
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0306acdaa8128d497edd16c0604024e8 https://doi.org/10.1093/annonc/mdy487.002 Zobrazit plný text záznamu